For the SLEEP 2024 conference, Rho co-authors, Ben Vaughn, Chief Strategist, Biostatistics & Protocol Design and Dr. Ihab Abdel-Fattah, Senior Medical Director, support Zevra in their upcoming presentation of the top line results of a Phase 2 study on the safety and efficacy of KP1077 in patients with idiopathic hypersomnia. KP1077 is an oral medication and proprietary drug used for the treatment of rare sleep disorders characterized by excessive daytime sleepiness (EDS), including idiopathic hypersomnia (IH).

Overall, KP1077 shows promise as a safe and effective treatment for patients with idiopathic hypersomnia.

Find the abstract here with the poster to be presented at SLEEP 2024, June 1-5.